Some major drugmakers are hesitating to participate in the Trump administration's speedier review program for new medicines ...

Today, we discuss Trump’s lofty new health plan, see the FDA delay two drug reviews under the new voucher program, and more.

This is the online version of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to ...

After getting demolished by the flu last week, I am thrilled to be back in the saddle. Stay healthy, everyone! President ...

When the new U.S. dietary guidelines came out last week, food economist William Masters emailed a few colleagues with a fun ...

WASHINGTON — President Trump on Thursday released a hodgepodge of health care policies that would create new price-control ...

The actual “how” of lifestyle medicine — meeting patients where they are, outside of the exam room — is crowded out of the ...

STAT's Alex Hogan breaks down #JPM26 on STATus Report: the mood, the big interviews — and all the AI billboards.

Health secretary Robert F. Kennedy Jr. said the changes were intended to restore trust in public health. But major health ...

The Novo Nordisk Foundation announced it was giving an additional $850 million to an institute to help commercialize biomedical research in Europe.

The FDA delayed reviews of two drugs chosen for the Trump administration's new fast-track program after agency scientists ...

You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and ...